Notice to attend the Extra General Meeting of Olink Holding AB (publ)
11. Juli 2024 16:05 ET
|
Olink Proteomics AB
This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, July 11, 2024 (GLOBE...
Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher
08. Juli 2024 07:37 ET
|
Olink Proteomics AB
UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK Competition and Markets Authority (the “CMA”) has unconditionally...
Report from the Extra General Meeting of Olink Holding AB (publ) on 5 July 2024
05. Juli 2024 16:15 ET
|
Olink Proteomics AB
UPPSALA, Sweden, July 05, 2024 (GLOBE NEWSWIRE) -- At the Extra General Meeting (the “EGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), the EGM adopted, inter alia, the...
Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery
03. Juli 2024 08:00 ET
|
Olink Proteomics AB
Inaugural network of Olink® Certified Service Providers includes eading contract research organizations (CROs) and service labs around the world.
Notice to attend the Extra General Meeting of Olink Holding AB (publ)
11. Juni 2024 09:00 ET
|
Olink Proteomics AB
This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, June 11, 2024 (GLOBE...
Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence
06. Juni 2024 02:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein...
Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
30. Mai 2024 08:00 ET
|
Olink Proteomics AB
Landmark study using the Olink Explore platform identifes proteins in the blood that may provide a 7-year warning for various cancers.
Olink reports first quarter 2024 financial results
13. Mai 2024 06:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024. ...
Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024
19. April 2024 16:05 ET
|
Olink Proteomics AB
UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), on 19 April 2024 the AGM adopted,...
Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease
02. April 2024 08:00 ET
|
Olink Proteomics AB
Olink delivers new open access data library consisting of over 300,000 protein-disease risk associations across 106 human diseases.